VIVO Cannabis Announces Appointment of Dr. Richa Love as Chief Medical Officer

NAPANEE, ON, Jan. 7, 2019 /CNW/ - VIVO Cannabis Inc. (TSX-V:VIVO, OTCQX: VVICF)("VIVO" or the "Company"), a licensed cannabis producer offering premium medical and adult-use products and services through its wholly-owned subsidiaries, ABcann Medicinals Inc. ("ABcann") and Canna Farms Ltd. ("Canna Farms"), today announce the appointment of Dr. Richa Love, MD, LMCC, CCFP, as the Company's Chief Medical Officer.

Dr. Love serves as Medical Director at Harvest Medicine, VIVO's wholly-owned network of specialty medical cannabis clinics that offer education, care, advice and follow-up support to their rapidly growing base of medical patients. She is also the founder and Chief Executive Officer at CannU, an online cannabis education and training resource for patients, consumers, retail workers and health care professionals.

"Throughout her career, Dr. Love has provided thousands of patients with cannabis assessments and has become an industry leader in helping patients improve their lives with cannabis," said Barry Fishman, Chief Executive Officer at VIVO. "As Chief Medical Officer at VIVO, Dr. Love will play a critical role in helping guide product development and innovation, along with serving as a valuable resource for our patients and team of healthcare and retail professionals. She makes a great addition to our team of medical experts and further strengthens our position as a leader in the medical cannabis space."

Dr. Love supports an integrated approach to patient wellness and is a passionate patient-advocate. She has spearheaded research exploring the effects of medical cannabis for a variety of medical conditions and hopes to use her findings to validate cannabinoid-based therapies and the development of new delivery mechanisms and formulations for specific medical conditions. Dr. Love's broad expertise will shape VIVO's approach to patient wellness and consumer education.

Dr. Love added, "In this role, I will support VIVO as the Company continues to develop a best-in-class medical cannabis offering, applying the rich insights I have gained through, my research into cannabinoid-based therapies and through the thousands of consultations I have had with patients seeking medical cannabis treatment."

Dr. Love received her medical degree from the University of Calgary in 1998 with a speciality in family practice from the University of Alberta. She has been nominated for the Outstanding Physician of the Year Award by the Alberta College of Family Physicians multiple times, has sat on several medical boards, and has been involved in physician governance, research, as well as advocacy and teaching.

Dr. Love will represent VIVO at the 2019 Lift & Co. Expo in Vancouver from January 11 to 13. Dr. Love will speak on two panels; she will share her experiences from when she first entered the medical cannabis space, explain the merits of certain cannabis applications, and discuss the latest in medical cannabis research, studies and treatments. To learn more about the Vancouver Lift & Co. Expo, visit: https://liftexpo.ca/vancouver19/.

About VIVO Cannabis™

VIVO, based in Napanee, Ontario, is recognized for trusted, high-quality products and services. It holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical™, FIRESIDE™, Canna Farms™ and Lumina™. In August 2018, VIVO acquired Canna Farms, a premium cannabis company based in Hope, British Columbia. Canna Farms was B.C.'s first Licensed Producer and has several years of craft cultivation experience and expertise, as well as a significant patient base and positive cash flow. The Company is significantly expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, including Germany and Australia. VIVO also operates Harvest Medicine, a patient-centric and highly scalable network of specialty medical cannabis clinics as well as a free telemedicine service. VIVO has a healthy balance sheet and is well-positioned to accelerate their growth in Canada and internationally.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements. These forward-looking statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. A more complete discussion of the risks and uncertainties facing the Company appears in the Company's Annual Information Form for the year ended December 31, 2017 and other continuous disclosure filings, which are available on SEDAR at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason, other than as required by applicable securities laws.

SOURCE VIVO Cannabis Inc.

VIVO Investor Relations, Heidi Christensen Brown, [email protected], +1.416-848-1389, NATIONAL Capital Markets; Michael Bumby, Chief Financial Officer, [email protected], VIVO Cannabis Inc.